Financial Trends -- 4/10
A high-quality GLP-1 franchise whose financial momentum has clearly rolled over. Revenue is
decelerating into outright decline (annual YoY collapsed from +25.0% in 2024 to +6.4% in 2025;
adjusted 2026Q1 net sales fell ~10.3% YoY), margins are compressing (~290 bps operating / ~370 bps
gross in 2025), and total borrowings rose ~5.7x over two years on the Catalent build-out. FCF is
positive on an annual basis but erratic and below its 2023 peak. Two mandatory penalty modifiers
apply: operating income declined while revenue grew (FY2025), and debt is growing faster than
revenue. Read-the-fine-print: reported 2026Q1 is inflated by a one-time ~DKK 26.76B 340B provision
reversal; every trajectory conclusion below uses the adjusted figure.
Weight: 25%
Margins
Compressing
Op -290 bps, gross -370 bps in 2025 | Negative
FCF
Erratic
Below 2023 peak; Q4s negative | Not growing
Total Borrowings
~5.7x
DKK 21.9B → 124.1B over 2 yrs | Rising fast
Quarterly Net Sales Trajectory (DKK M, reported)
Textbook deceleration into decline: +19.5% (Q1'25) to -10.3% adjusted (Q1'26).
Each comparable quarter's YoY rate is lower than the prior. The reported +24% optical for 2026Q1 is
false — it is distorted by a one-time ~DKK 26.76B 340B provision reversal; adjusted net sales of
DKK 70,063M
fell ~10.3% YoY. Consensus models 2026 as the earnings trough. This is the opposite of the rubric's
"accelerating" condition.
* 2026Q1 reported figures are 340B-distorted. † YoY computed on adjusted 2026Q1 net sales
(DKK 70,063M) vs 2025Q1.
Adjusted 2026Q1 -- The Clean Recurring Read
Annual Financial Summary (DKK M, FY ends December)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Net sales | 140,800 | 176,954 | 232,261 | 290,403 | 309,064 |
| Rev YoY | — | +25.7% | +31.3% | +25.0% | +6.4% |
| Gross profit | 117,142 | 148,506 | 196,496 | 245,881 | 250,276 |
| Gross margin | 83.2% | 83.9% | 84.6% | 84.7% | 81.0% |
| Operating profit | 58,644 | 74,809 | 102,574 | 128,339 | 127,658 |
| Operating margin | 41.6% | 42.3% | 44.2% | 44.2% | 41.3% |
| Diluted EPS (DKK) | 20.74 | 24.44 | 18.62 | 22.63 | 23.03 |
| Free cash flow | 29,319 | 57,362 | 68,326 | (14,707) | 28,295 |
| Total borrowings | — | — | 21,927 | 96,925 | 124,124 |
Key trends
- Revenue decelerating hard: Annual YoY collapsed from +25.0% (2024) to +6.4% (2025); the quarterly YoY ladder runs +19.5% → +12.9% → +5.1% → -7.6% → -10.3% (adj). Consensus models 2026 as the trough.
- Margins compressing: Gross margin fell ~370 bps (84.7% → 81.0%) and operating margin ~290 bps (44.2% → 41.3%) in 2025. Operating profit actually declined YoY in 2025 despite +6.4% revenue.
- Diluted EPS flat: DKK 22.63 (2024) → 23.03 (2025), +1.8% — a stall after years of double-digit growth.
- FCF below peak, erratic: DKK 68,326M (2023) → negative DKK -14,707M (2024, Catalent) → DKK 28,295M (2025). Positive on an annual basis but not durably growing.
- Debt up ~5.7x: Total borrowings DKK 21,927M (2023) → 96,925M (2024) → 124,124M (2025), growing far faster than revenue.
Segment Revenue (DKK M, Annual)
Drug-level reads confirm the deceleration. Ozempic fell from
DKK 32,721M
(2025Q1) to DKK 27,825M
(2026Q1), -15% YoY; total GLP-1 diabetes fell from
DKK 39,574M
to DKK 32,731M,
-17% YoY. Wegovy slowed to DKK 18,235M
(+5% YoY) versus a +85% YoY pace a year earlier.
Free Cash Flow (DKK M, quarterly -- seasonally non-comparable)
FCF positive on an annual basis but erratic, and NOT durably growing.
FY2023 FCF of DKK 68,326M was the peak; FY2024 went negative (Catalent); FY2025 recovered to only
DKK 28,295M, still well below 2023. Q4s are recurrently negative (Q4'24 -86.5B, Q4'25 -35.6B).
2026 guidance of DKK 36-46B is a recovery but still below the 2023 peak. Quarters are seasonally
non-comparable -- read Q1-vs-Q1 and Q4-vs-Q4 only.
Negatives -- Trajectory Has Rolled Over
| Item | Detail | Penalty |
|---|---|---|
| Op income declined, revenue grew | FY2025 net sales +6.4% yet operating profit fell from DKK 128,339M to DKK 127,658M (-0.5%) | -1 |
| Debt growing faster than revenue | Total borrowings up ~5.7x (DKK 21.9B → 124.1B) over two years vs ~33% cumulative revenue growth (Catalent/capacity build) | -1 |
| Revenue decelerating into decline | YoY ladder +19.5% → -10.3% (adj); annual +6.4% in 2025; consensus models 2026 as the trough | Band |
| Margins compressing | Gross -370 bps and operating -290 bps in 2025; adj Q1'26 op margin -280 bps YoY | Band |
Score Rationale
Score of 4/10 reflects a high-quality franchise whose financial momentum has clearly rolled over, with consensus itself underwriting 2026 as the earnings trough.
Why the low band:
- Revenue decelerating into negative (adjusted 2026Q1 -10.3% YoY; annual +6.4% in 2025, down from +25.0%)
- Margins compressing >100 bps (gross -370 bps, operating -290 bps in 2025)
- FCF positive on an annual basis but erratic and below its 2023 peak (not durably growing)
- Share count essentially flat (no dilution, but no buyback tailwind)
Penalty modifiers applied:
- -1 operating income declined while revenue grew (FY2025)
- -1 debt growing faster than revenue for 3+ periods (2023 → 2024 → 2025)
What prevents a lower score: still-positive annual FCF, dominant ~81-84% gross margins, and a guided 2026 FCF stabilization (DKK 36-46B) lift the base read off the floor to 4/10.
Composite quality gate — positiveGrowingFcf: NO. FCF is positive on a TTM/annual basis but not durably growing and highly erratic (DKK 68,326M in 2023 → negative in 2024 → 28,295M in 2025).
Data sourced from Daloopa (company_id: 50204). Reporting currency DKK; fiscal year ends December 31. Price/market cap from FMP (Bloomberg MCP unavailable this run).